X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (4904) 4904
Newsletter (428) 428
Publication (358) 358
Book Review (342) 342
Book Chapter (27) 27
Conference Proceeding (16) 16
Magazine Article (14) 14
Dissertation (10) 10
Newspaper Article (4) 4
Web Resource (2) 2
Government Document (1) 1
Reference (1) 1
Streaming Video (1) 1
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (3450) 3450
humans (2999) 2999
pyrazinamide (2938) 2938
tuberculosis (2066) 2066
male (1491) 1491
female (1430) 1430
pyrazinamide - therapeutic use (1259) 1259
adult (1251) 1251
antitubercular agents - therapeutic use (1195) 1195
isoniazid - therapeutic use (970) 970
tuberculosis, pulmonary - drug therapy (964) 964
rifampin - therapeutic use (958) 958
middle aged (899) 899
drug therapy, combination (850) 850
mycobacterium tuberculosis - drug effects (808) 808
rifampin (726) 726
isoniazid (710) 710
pyrazinamide - pharmacology (698) 698
microbiology (682) 682
pyrazinamide - administration & dosage (673) 673
tuberculosis - drug therapy (646) 646
infectious diseases (642) 642
pharmacology & pharmacy (630) 630
antitubercular agents - administration & dosage (615) 615
animals (588) 588
antitubercular agents - pharmacology (578) 578
rifampin - administration & dosage (578) 578
isoniazid - administration & dosage (540) 540
ethambutol - therapeutic use (530) 530
adolescent (523) 523
aged (489) 489
mycobacterium-tuberculosis (479) 479
drug therapy (463) 463
antitubercular agents - adverse effects (459) 459
respiratory system (440) 440
drugs (421) 421
research (418) 418
rifampicin (418) 418
treatment outcome (407) 407
pulmonary tuberculosis (404) 404
mycobacterium tuberculosis (401) 401
ethambutol (399) 399
abridged index medicus (392) 392
drug resistance (363) 363
pyrazinamide - adverse effects (361) 361
time factors (345) 345
microbial sensitivity tests (344) 344
mycobacterium tuberculosis - isolation & purification (341) 341
antitubercular agents (315) 315
child (309) 309
old medline (296) 296
analysis (279) 279
mice (279) 279
drug resistance, microbial (271) 271
mycobacterium tuberculosis - genetics (271) 271
drug administration schedule (267) 267
ethambutol - administration & dosage (264) 264
immunology (260) 260
streptomycin - therapeutic use (260) 260
drug resistance in microorganisms (259) 259
chemotherapy (255) 255
rifampin - adverse effects (249) 249
pharmacokinetics (242) 242
isoniazid - adverse effects (233) 233
tuberculosis, multidrug-resistant - drug therapy (227) 227
susceptibility (224) 224
medicine, general & internal (222) 222
antitubercular agents - pharmacokinetics (221) 221
tuberculosis, pulmonary - microbiology (219) 219
risk factors (216) 216
mutation (207) 207
isoniazid - pharmacology (203) 203
drug combinations (196) 196
antituberculosis drugs (195) 195
young adult (193) 193
follow-up studies (181) 181
infection (176) 176
pyrazinamide - analogs & derivatives (176) 176
tuberculosis - microbiology (176) 176
moxifloxacin (175) 175
resistance (175) 175
child, preschool (174) 174
rifampin - pharmacology (173) 173
streptomycin - administration & dosage (173) 173
health aspects (171) 171
hepatotoxicity (170) 170
streptomycin (170) 170
rifampin - pharmacokinetics (168) 168
sputum - microbiology (166) 166
diagnosis (164) 164
pyrazinamide - pharmacokinetics (164) 164
dosage and administration (163) 163
retrospective studies (161) 161
antibiotics, antitubercular - therapeutic use (152) 152
uric acid - metabolism (151) 151
pharmacology (148) 148
recurrence (148) 148
therapy (147) 147
infant (146) 146
uric acid - blood (146) 146
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (4526) 4526
French (175) 175
German (127) 127
Spanish (110) 110
Italian (104) 104
Japanese (101) 101
Russian (80) 80
Polish (47) 47
Chinese (31) 31
Portuguese (26) 26
Korean (15) 15
Turkish (15) 15
Hungarian (13) 13
Dutch (7) 7
Czech (4) 4
Norwegian (3) 3
Romanian (3) 3
Swedish (3) 3
Hebrew (2) 2
Serbian (2) 2
Bulgarian (1) 1
Danish (1) 1
Persian (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


La Revue de medecine interne, ISSN 0248-8663, 12/2018, Volume 39, p. A196
Le syndrome d'hypersensibilite medicamenteuse ou Drug Rash with Eosinophilia and Systemic Symptoms (DRESS) est une toxidermie grave associant une eruption... 
Pyrazinamide
Journal Article
International Journal of Pharmaceutics, ISSN 0378-5173, 02/2015, Volume 479, Issue 1, p. 163
Display Omitted 
Pyrazinamide
Journal Article
Revue Francaise d'Allergologie, ISSN 1877-0320, 04/2017, Volume 57, Issue 3, p. 258
To access, purchase, authenticate, or subscribe to the full-text of this article, please visit this link: http://dx.doi.org/10.1016/j.reval.2017.02.124 Les... 
Pyrazinamide
Journal Article
Revue Francaise d'Allergologie, ISSN 1877-0320, 04/2017, Volume 57, Issue 3, p. 261
To access, purchase, authenticate, or subscribe to the full-text of this article, please visit this link: http://dx.doi.org/10.1016/j.reval.2017.02.131 Les... 
Pyrazinamide
Journal Article
Revue Francaise d'Allergologie, ISSN 1877-0320, 04/2017, Volume 57, Issue 3, p. 261
To access, purchase, authenticate, or subscribe to the full-text of this article, please visit this link: http://dx.doi.org/10.1016/j.reval.2017.02.133 Le choc... 
Pyrazinamide
Journal Article
Science, ISSN 0036-8075, 9/2011, Volume 333, Issue 6049, pp. 1630 - 1632
Pyrazinamide (PZA) is a first-line tuberculosis drug that plays a unique role in shortening the duration of tuberculosis chemotherapy. PZA is hydrolyzed... 
Proteins | Tuberculosis | Mycobacterium tuberculosis | REPORTS | Ribosomes | Power of attorney | Amino acids | Bacteria | Geometric lines | Codons | Genetic mutation | PYRAZINOIC ACID | SYNTHASE | MESSENGER-RNA | MULTIDISCIPLINARY SCIENCES | ESCHERICHIA-COLI | SUSCEPTIBILITY | RESISTANCE | PNCA MUTATIONS | BINDING | RIBOSOMAL-PROTEIN S1 | TMRNA | Ribosomal Proteins - chemistry | Bacterial Proteins - chemistry | Drug Resistance, Bacterial | Molecular Sequence Data | Ribosomes - metabolism | RNA, Messenger - metabolism | Mycobacterium tuberculosis - drug effects | Prodrugs - metabolism | Ribosomal Proteins - metabolism | Pyrazinamide - pharmacology | Mycobacterium tuberculosis - metabolism | RNA, Bacterial - metabolism | Pyrazinamide - metabolism | Amidohydrolases - metabolism | Protein Structure, Tertiary | Amino Acid Sequence | Pyrazinamide - analogs & derivatives | RNA, Transfer - metabolism | Ribosomal Proteins - genetics | Amidohydrolases - genetics | Antitubercular Agents - pharmacology | Bacterial Proteins - genetics | Mutant Proteins - metabolism | Protein Binding | Bacterial Proteins - metabolism | Protein Biosynthesis - drug effects | Mutation | Antitubercular Agents - metabolism | Prodrugs - pharmacology | Mycobacterium tuberculosis - genetics | Physiological aspects | Development and progression | Genetic aspects | Research | Pyrazinamide | Health aspects | Genetic translation | Enzymes | Chemotherapy | Inhibitor drugs | Index Medicus
Journal Article
Journal Article
Journal Article
Antimicrobial Agents and Chemotherapy, ISSN 0066-4804, 06/2012, Volume 56, Issue 6, pp. 3114 - 3120
Journal Article
Clinical Infectious Diseases, ISSN 1058-4838, 05/2017, Volume 64, Issue 10, pp. 1350 - 1359
Background. There is scant evidence to support target drug exposures for optimal tuberculosis outcomes. We therefore assessed whether... 
pharmacokinetic-pharmacodynamic variability | drug-drug antagonism | minimum inhibitory concentrations | Mycobacterium tuberculosis | tuberculosis treatment outcomes | MYCOBACTERIUM-TUBERCULOSIS | INFECTIOUS DISEASES | RIFAMPIN | MICROBIOLOGY | IMMUNOLOGY | PHARMACOKINETICS-PHARMACODYNAMICS | PLASMA | BACTERICIDAL ACTIVITY | STERILIZING ACTIVITY | PREDICT | RESISTANCE | PYRAZINAMIDE | OUTCOMES | Sputum - microbiology | Tuberculosis, Pulmonary - microbiology | Isoniazid - pharmacology | Rifampin - pharmacokinetics | Rifampin - blood | Coinfection - drug therapy | Humans | Middle Aged | Male | Tuberculosis, Pulmonary - drug therapy | Mycobacterium tuberculosis - drug effects | Tuberculosis, Pulmonary - complications | Microbial Sensitivity Tests | Pyrazinamide - pharmacology | Drug Interactions | Mycobacterium tuberculosis - physiology | Adult | Female | Isoniazid - therapeutic use | Rifampin - therapeutic use | Drug Therapy, Combination | Isoniazid - antagonists & inhibitors | Antitubercular Agents - therapeutic use | Pyrazinamide - administration & dosage | Isoniazid - pharmacokinetics | Pyrazinamide - pharmacokinetics | Antitubercular Agents - pharmacology | Logistic Models | Treatment Outcome | Pyrazinamide - blood | Coinfection - virology | Mycobacterium tuberculosis - isolation & purification | Coinfection - microbiology | Antitubercular Agents - pharmacokinetics | HIV Infections - complications | Rifampin - pharmacology | Mycobacterium tuberculosis - growth & development | Treatment outcome | Care and treatment | Research | Antibiosis | Analysis | Pulmonary tuberculosis | Therapy | Splines | Lung | Viruses | Optimization | Antagonism | Human immunodeficiency virus--HIV | Mathematical models | Isoniazid | Culture | Thresholds | Adjustment | Pharmacology | Exposure | Regression analysis | Pyrazinamide | Patients | Conversion | Prescription drugs | Tuberculosis | Sputum | Minimum inhibitory concentration | Nonlinearity | Models | Rifampin | Index Medicus | Major | drug–drug antagonism
Journal Article
PLOS ONE, ISSN 1932-6203, 09/2018, Volume 13, Issue 9, pp. e0204495 - e0204495
New therapeutic strategies are needed to treat drug resistant tuberculosis (TB) and to improve treatment for drug sensitive TB. Pyrazinamide (PZA) is a... 
EXPERIMENTAL AIRBORNE TUBERCULOSIS | ANTIMYCOBACTERIAL ACTIVITY | PYRAZINAMIDE RESISTANCE | MURINE MODEL | IN-VITRO | STERILIZING ACTIVITY | ANTITUBERCULOSIS AGENTS | MULTIDISCIPLINARY SCIENCES | DRUG DISCOVERY | ESTERS | RESISTANT MYCOBACTERIUM-TUBERCULOSIS | Granuloma, Respiratory Tract - pathology | Tuberculosis, Pulmonary - microbiology | Granuloma, Respiratory Tract - drug therapy | Male | Tuberculosis, Pulmonary - drug therapy | Mycobacterium tuberculosis - drug effects | Necrosis | Granuloma, Respiratory Tract - microbiology | Rifampin - administration & dosage | Drug Therapy, Combination | Tuberculosis, Multidrug-Resistant - pathology | Disease Models, Animal | Pyrazinamide - administration & dosage | Dry Powder Inhalers | Guinea Pigs | Pyrazinamide - analogs & derivatives | Pyrazinamide - pharmacokinetics | Bacterial Load | Respiratory Tract Absorption | Tuberculosis, Pulmonary - pathology | Animals | Antitubercular Agents - pharmacokinetics | Aerosols | Antitubercular Agents - administration & dosage | Tuberculosis, Multidrug-Resistant - drug therapy | Drugs | Usage | Drug delivery systems | Tuberculosis | Development and progression | Dosage and administration | Drug therapy | Pyrazinamide | Health aspects | Testing | Vehicles | Spleen | Therapy | Bacilli | Liver | Infections | Drug resistance | Powder | Critical components | Medicine | Chemotherapy | Immunology | Acids | Lungs | Guinea pigs | Sterilization | Drug dosages | Rifampin | Index Medicus
Journal Article
Journal Article
La Revue de medecine interne, ISSN 0248-8663, 06/2016, Volume 37, p. A185
La tuberculose genitale (TG) de la femme fait partie des formes rares et peu connues des tuberculoses extra-pulmonaires touchant essentiellement les femmes... 
Pyrazinamide | Tuberculosis
Journal Article
Antimicrobial Agents and Chemotherapy, ISSN 0066-4804, 06/2012, Volume 56, Issue 6, pp. 3027 - 3031
Journal Article
The Journal of Infectious Diseases, ISSN 0022-1899, 11/2013, Volume 208, Issue 9, pp. 1464 - 1473
Journal Article